News
RNAZ
8.90
+1.14%
0.10
Weekly Report: what happened at RNAZ last week (0406-0410)?
Weekly Report · 1d ago
Transcode Therapeutics signs flexible financing agreement for up to $20M
TipRanks · 04/07 14:29
TransCode Therapeutics Secures New Financing to Extend Runway
TipRanks · 04/07 13:06
TransCode Therapeutics Enters Into Agreement With Institutional Healthcare Investor For Financing Of Up To $20M
Benzinga · 04/07 12:37
TRANSCODE THERAPEUTICS ENTERS INTO AGREEMENTS FOR UP TO $20 MILLION FLEXIBLE FINANCING, EXTENDING COMPANY'S RUNWAY INTO LATE 2027/EARLY 2028
Reuters · 04/07 12:30
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
PR Newswire · 04/07 12:30
Weekly Report: what happened at RNAZ last week (0330-0403)?
Weekly Report · 04/06 09:24
TransCode Therapeutics Delays 2025 Annual Filing
TipRanks · 04/01 02:25
TransCode Therapeutics delays annual report filing, cites complex accounting for transactions
Reuters · 03/31 20:20
Weekly Report: what happened at RNAZ last week (0323-0327)?
Weekly Report · 03/30 09:24
Weekly Report: what happened at RNAZ last week (0316-0320)?
Weekly Report · 03/23 09:23
Weekly Report: what happened at RNAZ last week (0309-0313)?
Weekly Report · 03/16 09:22
Weekly Report: what happened at RNAZ last week (0302-0306)?
Weekly Report · 03/09 09:23
TransCode Therapeutics Issues 1.14M Non-Voting Convertible Preferred Shares in Private Placement
Reuters · 03/03 21:54
TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal
TipRanks · 03/03 21:37
TransCode Therapeutics Enters Into Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement With Unleash Immuno Oncolytics
Benzinga · 03/03 13:19
Transcode Therapeutics enters exclusive license agreement with Unleash
TipRanks · 03/03 13:13
TRANSCODE THERAPEUTICS INC - UNDER AGREEMENT, UNLEASH TO RECEIVE 1,136,364 SHARES OF TRANSCODE PREFERRED STOCK
Reuters · 03/03 13:11
TransCode Therapeutics Secures Royalty-Free Worldwide License for Oncolytic Immunotherapy Candidates
Reuters · 03/03 13:03
TransCode Therapeutics licenses Unleash oncolytic immunotherapy platform in all-stock deal
Reuters · 03/03 13:01
More
Webull provides a variety of real-time RNAZ stock news. You can receive the latest news about Transcode Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.